Thirty Madison
- 🦄Became a unicorn2021
- 📈Peak valuation$1 Billion ’21
- 💔Became a Unitard~2023
- 💸Last valuation~$500M
How it happened
Thirty Madison is a US digital-health company operating condition-focused telehealth brands, and reached a ~$1B valuation in 2021, the same year it merged with women's-health provider Nurx. As healthtech valuations corrected, third-party estimates (PitchBook) marked it down by roughly half, pushing it below the unicorn threshold. Glassdoor reviews from the correction describe a bumpy stretch: employees recounted substantial layoffs in each of the next few years and said the company's reported profitability owed more to those cuts, attrition and trimmed benefits than to growth. Many also described the Nurx integration as chaotic and noted bonuses shifting from cash to restricted stock amid frequent strategy shifts.
Employee accounts paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗. See our methodology.
Mutual-fund markdowns
1 fund · SEC NPORT-PHow U.S. mutual funds fair-value this still-private company in their quarterly SEC filings.
Source: SEC EDGAR Form NPORT-P (Level-3 fair-value marks). Per-share marks reflect the fund’s own valuation of a specific share class and aren’t a company-wide valuation. Last refreshed Jun 2026.
Source: PitchBook estimate, reported by CNBC (Jun 2026)
